Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female between the ages of 18 and 70 years diagnosed with type 2 diabetes.~* Body mass index (BMI) between 18 kg/m2 and 37 kg/m2 (inclusive).~* HbA1c levels between 6.5 and 9.5 (inclusive) where the upper limit of normal for the HbA1c assay is 6.4% or HbA1c levels between 6.2 and 9.5% (inclusive) where the upper limit of normal for the HbA1c assay is 6.1%.~* Fasting plasma glucose levels between 126 and 270 mg/dL (7 - 15 mmol/L, inclusive) while on diabetic medications.~* Treatment naïve subjects with HbA1c between 6.5 and 9.5 and fasting plasma glucose between 126 and 270 mg/dL (7 - 15 mmol/L).~* If taking drugs for diabetes, must be medically able and willing to discontinue diabetic medications for the duration of the study.~* Female subjects must be surgically sterilized or postmenopausal.~Exclusion Criteria:~* Type 1 diabetes or diabetes treated with insulin injection.~* Insulin therapy or oral antidiabetic medication other than metformin, sitagliptin, saxagliptin, a sulfonylurea or combination of these.~* Sitting blood pressure above 150/95 mmHg on two evaluations at least 10 minutes apart at screening.~* Positive results on screen for drugs of abuse.~* Previous treatment with an investigational drug within 30 days or 7 half-lives, whichever is longer.~* Previous treatment with EGT0001474 or EGT0001442.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- EGT0001442 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).